International Diabetes Federation

Global HbA1c Analyzers Market Analysis Report 2024-2031 - Leading Market Players Drive Growth Amidst Rising Prevalence of Diabetes and Technological Advancements - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 24, 2024
Health, Diabetes, International Diabetes Federation, Vaccination, Glycated hemoglobin, Disorder, Incidence, Diagnosis, COVID-19, Prevalence, Pharmaceutical industry

In this context, the demand for HbA1c analyzers is set to rise significantly, as hemoglobin measurement remains integral in diagnosing and managing diabetes.

Key Points: 
  • In this context, the demand for HbA1c analyzers is set to rise significantly, as hemoglobin measurement remains integral in diagnosing and managing diabetes.
  • The market is poised to benefit from the growing necessity for efficient diagnostic tools amidst the surge in diabetes cases globally.
  • Moreover, the utilization of HbA1c analyzers for pre-surgery glucose assessments is further fueling market growth, presenting lucrative opportunities for market players.
  • The HbA1c analyzers market presents a moderately competitive landscape, characterized by the presence of both domestic and foreign players, with global giants dominating the scene.

Drug Infusion Systems Global Market Report 2024: Demand for Personalized Medicine and Adaptive Dosing Spurs Growth - Long-term Forecast to 2028 and 2033 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 18, 2024
Health, Pharmaceutical, International Diabetes Federation, Conditional sentence, Cancer, IDF, Informatics, Hospital, Diabetes, EHR, Health care, EMR, Paratriathlon, ADT, Stroke, Amputation, Health information management, Patient, Splenic infarction, Kidney, Prevalence, Ageing, Medical device

The drug infusion systems market is expected to see strong growth in the next few years.

Key Points: 
  • The drug infusion systems market is expected to see strong growth in the next few years.
  • Asia-Pacific is expected to be the fastest-growing region in the global drug infusion systems market report during the forecast period.
  • Global Drug Infusion Systems Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
    6.1.
  • Global Drug Infusion Systems Market, Segmentation by Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

Global Point of Care Testing (POCT) Market Report 2023-2030: Continued Expansion of Point of Care Including Self Testing Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 15, 2024
Nursing, Medical Supplies, Health, Hospitals, General Health, Biotechnology, Diabetes, Medical microbiology, LFA, Infection, Mortality, Conditional sentence, Patient, Mode, Incidence, Diagnosis, Developed country, Clinic, Cancer, Government, Workplace, International Diabetes Federation, Point-of-care testing, Prevalence, POC, Nature, POCT, Physician, Growth, Medical device

The "Global Point of Care Testing Market (By Diagnostics Segment, Mode, End Users, Regions), 100 Company Profiles" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Point of Care Testing Market (By Diagnostics Segment, Mode, End Users, Regions), 100 Company Profiles" report has been added to ResearchAndMarkets.com's offering.
  • Hence, the growing infectious diseases and chronic conditions will drive the point of care testing market over the forecast period.
  • Based on diagnostics segment, the point of care testing market is dominated by blood glucose testing segment.
  • The point of care testing market for immunoassays technology is expected to witness significant growth over the forecast timeframe.

International Diabetes Federation and Sanofi Global Health Unit collaborate to strengthen diabetes response in 40 countries

Retrieved on: 
Tuesday, January 16, 2024
Online, Diabetes, IDF, Knowledge, Partnership, Pharmacist, Nursing, International Diabetes Federation, GHU, Sanofi, Diagnosis, Pharmaceutical industry

BRUSSELS, Jan. 16, 2024 /PRNewswire/ -- The International Diabetes Federation (IDF), in collaboration with Sanofi's Global Health Unit (GHU), is taking significant steps to improve access to diabetes care. The collaboration aims to support the early diagnosis, management and prevention of diabetes and its complications by training a minimum of 4,000 healthcare professionals (HCPs) in low and middle-income countries (LMICs) under-prepared to address the growing number of people living with diabetes.

Key Points: 
  • BRUSSELS, Jan. 16, 2024 /PRNewswire/ -- The International Diabetes Federation (IDF) , in collaboration with Sanofi's Global Health Unit (GHU), is taking significant steps to improve access to diabetes care.
  • The partnership will enhance the diabetes knowledge and skills of HCPs, particularly primary care physicians, nurses, diabetes educators and pharmacists in 40 countries.
  • According to the IDF Diabetes Atlas, the majority of the more than half a billion individuals now living with diabetes worldwide are found in LMICs.
  • "Sanofi's Global Health Unit is committed to ensuring access to affordable, equitable and sustainable healthcare in 40 of the most vulnerable countries around the world.

International Diabetes Federation and Sanofi Global Health Unit collaborate to strengthen diabetes response in 40 countries

Retrieved on: 
Tuesday, January 16, 2024
Online, Diabetes, IDF, Knowledge, Partnership, Pharmacist, Nursing, International Diabetes Federation, GHU, Sanofi, Diagnosis, Pharmaceutical industry

BRUSSELS, Jan. 16, 2024 /PRNewswire/ -- The International Diabetes Federation (IDF), in collaboration with Sanofi's Global Health Unit (GHU), is taking significant steps to improve access to diabetes care. The collaboration aims to support the early diagnosis, management and prevention of diabetes and its complications by training a minimum of 4,000 healthcare professionals (HCPs) in low and middle-income countries (LMICs) under-prepared to address the growing number of people living with diabetes.

Key Points: 
  • BRUSSELS, Jan. 16, 2024 /PRNewswire/ -- The International Diabetes Federation (IDF) , in collaboration with Sanofi's Global Health Unit (GHU), is taking significant steps to improve access to diabetes care.
  • The partnership will enhance the diabetes knowledge and skills of HCPs, particularly primary care physicians, nurses, diabetes educators and pharmacists in 40 countries.
  • According to the IDF Diabetes Atlas, the majority of the more than half a billion individuals now living with diabetes worldwide are found in LMICs.
  • "Sanofi's Global Health Unit is committed to ensuring access to affordable, equitable and sustainable healthcare in 40 of the most vulnerable countries around the world.

LiveCare Inc. Ushers in a New Era of Telehealth in Dubai with Historic Licensing Achievement

Retrieved on: 
Friday, December 15, 2023
Letter, Prevalence, Hope, Health, Diabetes, International Diabetes Federation, Telehealth, IDF, Growth, Optimism, OTC

This monumental achievement marks a significant milestone in the evolution of healthcare services in the region and heralds a new chapter of growth for LiveCare Inc.

Key Points: 
  • This monumental achievement marks a significant milestone in the evolution of healthcare services in the region and heralds a new chapter of growth for LiveCare Inc.
  • This first step towards establishing a telehealth center in Dubai Healthcare City, serving the United Arab Emirates (UAE) and other countries in the region, is subject to the completion of all licensing and other requirements prior to initiating operations.
  • LiveCare Inc.'s expansion into the UAE is a testament to the company's dedication to transforming the healthcare landscape.
  • By leveraging advanced technology and a patient-centric approach, LiveCare is set to make a substantial impact on the health and well-being of the UAE's residents.

Know how to manage and prevent diabetes for a better life

Retrieved on: 
Tuesday, November 14, 2023
Well, Consensus, Chinese, World Diabetes Day, EASD, Consensus decision-making, Food, Chapter, Risk, American Diabetes Association, IDF, Patient, To Brazil!, ANAD, Sugar, WDD, Social media, Friends, International Diabetes Federation, Person, ISA, Family, Quality of life, Dietary supplement, Soft drink, Nutrition, Diabetes

Knowing your risk of type 2 diabetes to help delay or prevent the condition is important.

Key Points: 
  • Knowing your risk of type 2 diabetes to help delay or prevent the condition is important.
  • Alongside other cornerstones of diabetes management, a healthy diet has the potential to improve glucose control, reduce the risk of diabetes complications and improve quality of life.
  • More information about World Diabetes Day 2023 is available on the WDD website available at: https://worlddiabetesday.org
    IDF, Diabetes Atlas 10th edition 2021.
  • Consenso de la Asociación Latinoamericana de Diabetes sobre uso de edulcorantes no calóricos en personas con diabetes [Consensus of the Latin-American Association of Diabetes on low calorie sweeteners in persons with diabetes].

United States Health Insurance Market Analysis Report 2023: A $1,639 Billion Industry by 2028 from $1,150 Billion in 2022 - Competition, Forecasts and Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, December 15, 2023
Health, Health Insurance, Preferred provider organization, United States Census Bureau, Medicaid, Conditional sentence, Affordable Care Act, Prevalence, California Insurance Commissioner, International Diabetes Federation, Cardiovascular disease, Insurance, Elevance Health, Patient, National Association, USD, Telehealth, Health maintenance organization, NAIC, COVID-19, ACA, Cancer, Plasma protein binding, POS, Growth, Hospital, Diabetes, DSM-IV codes, Trump, Health insurance, Cigna

The "United States Health Insurance Market Competition, Forecast and Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Health Insurance Market Competition, Forecast and Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.
  • United States health insurance market is expected to reach a value of $1639.44 billion by 2028, up from $1150.23 billion in 2022, driven by the increasing private health insurance provider and rising medical expenditures during the forecast period.
  • The United States health insurance market has experienced significant growth over the past decade, driven by several factors, such as rising healthcare costs, increasing awareness of health insurance, and a surging population.
  • The United States offers ample opportunities for health insurance companies to expand their offerings beyond traditional health insurance products.

Type 1 Diabetes Market to Accelerate Substantially During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Dompé Farmaceutici

Retrieved on: 
Wednesday, November 15, 2023
Meal, Novo Nordisk, T1D, Prevalence, Therapy, Insulin, Weight loss, Abdominal pain, Eating, Disease, International Diabetes Federation, IDF, Fatigue, Autoantibody, Pancreas, Random glucose test, Finerenone, Urination, Health, Eli Lilly, Eli Lilly and Company, Diabetes, Gestational diabetes, Hunger, Hyperglycemia, Xerostomia, Type 1, Glycated hemoglobin, Glucose, LAS, Overalls, Vertex Pharmaceuticals, Type 2 diabetes, Hypoglycemia, Pharmaceutical industry, Dietary supplement, Bayer

LAS VEGAS, Nov. 15, 2023 /PRNewswire/ -- DelveInsight's Type 1 Diabetes Market Insights report includes a comprehensive understanding of current treatment practices, type 1 diabetes emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • According to the International Diabetes Federation (IDF), Type 1 diabetes may affect anybody at any age, although it impacts children and adolescents the most commonly.
  • Over 1 million children and adolescents under the age of 20 have type 1 diabetes.
  • Diabetes is medically categorized into three primary types, with Type 1 diabetes, Type 2 diabetes, and gestational diabetes being the main classifications.
  • To know more about type 1 diabetes treatment, visit @ Type 1 Diabetes Treatment Drugs

Type 1 Diabetes Market to Accelerate Substantially During the Study Period (2019-2032), Predicts DelveInsight | Leading Companies Developing Therapies - Eli Lilly, Vertex, Bayer, Novo Nordisk, Rise, Tolerion, BioKier, Dompé Farmaceutici

Retrieved on: 
Wednesday, November 15, 2023
Meal, Novo Nordisk, T1D, Prevalence, Therapy, Insulin, Weight loss, Abdominal pain, Eating, Disease, International Diabetes Federation, IDF, Fatigue, Autoantibody, Pancreas, Random glucose test, Finerenone, Urination, Health, Eli Lilly, Eli Lilly and Company, Diabetes, Gestational diabetes, Hunger, Hyperglycemia, Xerostomia, Type 1, Glycated hemoglobin, Glucose, LAS, Overalls, Vertex Pharmaceuticals, Type 2 diabetes, Hypoglycemia, Pharmaceutical industry, Dietary supplement, Bayer

LAS VEGAS, Nov. 15, 2023 /PRNewswire/ -- DelveInsight's Type 1 Diabetes Market Insights report includes a comprehensive understanding of current treatment practices, type 1 diabetes emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • According to the International Diabetes Federation (IDF), Type 1 diabetes may affect anybody at any age, although it impacts children and adolescents the most commonly.
  • Over 1 million children and adolescents under the age of 20 have type 1 diabetes.
  • Diabetes is medically categorized into three primary types, with Type 1 diabetes, Type 2 diabetes, and gestational diabetes being the main classifications.
  • To know more about type 1 diabetes treatment, visit @ Type 1 Diabetes Treatment Drugs